研究报告 |
|
|
|
|
靶向PSMA多价纳米抗体的制备及其生物学活性表征* |
鲍奕恺,洪皓飞**(),施杰,周志昉,吴志猛**() |
江南大学生物工程学院 糖化学与生物技术教育部重点实验室 无锡 214122 |
|
Development and Biological Activity Analysis of PSMA Specific Mutivalent Nanobodies |
BAO Yi-kai,HONG Hao-fei**(),SHI Jie,ZHOU Zhi-fang,WU Zhi-meng**() |
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China |
引用本文:
鲍奕恺,洪皓飞,施杰,周志昉,吴志猛. 靶向PSMA多价纳米抗体的制备及其生物学活性表征*[J]. 中国生物工程杂志, 2022, 42(5): 37-45.
BAO Yi-kai,HONG Hao-fei,SHI Jie,ZHOU Zhi-fang,WU Zhi-meng. Development and Biological Activity Analysis of PSMA Specific Mutivalent Nanobodies. China Biotechnology, 2022, 42(5): 37-45.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2201019
或
https://manu60.magtech.com.cn/biotech/CN/Y2022/V42/I5/37
|
[1] |
Wild C P, Weiderpass E, Stewart B W. World cancer report:cancer research for cancer prevention. 2020 ed. Lyon: International Agency for Research on Cancer, 2020:2 8-33: 421-429.
|
[2] |
邓通, 蔡林, 陈征, 等. 1990年与2017年中国前列腺癌疾病负担分析. 医学新知, 2020, 30(4): 252-259.
|
|
Deng T, Cai L, Chen Z, et al. Analysis of the burden of prostate cancer in China in 1990 and 2017. New Medicine, 2020, 30(4): 252-259.
|
[3] |
Liu X, Yu C, Bi Y, et al. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health, 2019, 172: 70-80.
doi: S0033-3506(19)30140-4
pmid: 31220754
|
[4] |
Israeli R S, Powell C T, Fair W R, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Research, 1993, 53(2): 227-230.
pmid: 8417812
|
[5] |
Sokoloff R L, Norton K C, Gasior C L, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. The Prostate, 2000, 43(2): 150-157.
doi: 10.1002/(SICI)1097-0045(20000501)43:2<150::AID-PROS10>3.0.CO;2-B
|
[6] |
Bostwick D G, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer, 1998, 82(11): 2256-2261.
pmid: 9610707
|
[7] |
Silver D A, Pellicer I, Fair W R, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research, 1997, 3(1): 81-85.
pmid: 9815541
|
[8] |
刘冲, 陶嵘. 前列腺特异性膜抗原为靶标的放射免疫治疗进展. 肿瘤影像学, 2015, 24(3): 168-172.
|
|
Liu C, Tao R. Advances in radioimmunotherapy targeting prostate specific membrane antigen in prostate cancer. Oncoradiology, 2015, 24(3): 168-172.
|
[9] |
焦点. PSMA在多种肿瘤中的表达分析及靶向PSMA的抗体偶联药物用于前列腺癌治疗的研究. 西安: 中国人民解放军空军军医大学, 2019.
|
|
Jiao D. Study of PSMA Expression in various tumors and treatment on prostate cancer using psma-based antibody-drug conjugate. Xian: Air Force Medical University of PLA, 2019.
|
[10] |
Ghosh A, Heston W D W. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal of Cellular Biochemistry, 2004, 91(3): 528-539.
doi: 10.1002/jcb.10661
|
[11] |
Mir M A, Mehraj U, Sheikh B A, et al. Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics. Human Antibodies, 2020, 28(1): 29-51.
doi: 10.3233/HAB-190390
|
[12] |
李丹, 黄鹤. 纳米抗体异源表达的研究进展. 中国生物工程杂志, 2017, 37(8): 84-95.
|
|
Li D, Huang H. Heterologous expression of nanobodies: a recent progress. China Biotechnology, 2017, 37(8): 84-95.
|
[13] |
Fan X Z, Wang L F, Guo Y L, et al. Ultrasonic nanobubbles carrying anti-PSMA nanobody: construction and application in prostate cancer-targeted imaging. PLoS One, 2015, 10(6): e0127419.
doi: 10.1371/journal.pone.0127419
|
[14] |
Chatalic K L S, Veldhoven-Zweistra J, de Ridder C M A, et al. SPECT/CT and PET imaging of prostate cancer xenografts using a novel anti-PSMA nanobody. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41: S319-S320.
|
[15] |
范校周. 携载PSMA纳米抗体的超声纳米泡在靶向诊断前列腺癌中的实验研究. 重庆: 第三军医大学, 2014.
|
|
Fan X Z. Experimental study of ultrasound nanobubble coupled with anti-PSMA nanobody in the targeting diagnosis of prostate cancer. Chongqing: Third Military Medical University, 2014.
|
[16] |
Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z. Nanobody;an old concept and new vehicle for immunotargeting. Immunological Investigations, 2011, 40(3): 299-338.
doi: 10.3109/08820139.2010.542228
pmid: 21244216
|
[17] |
王长江, 曲光刚, 武曰星, 等. 猪圆环病毒2型Cap蛋白特异性双价纳米抗体原核表达及活性鉴定. 动物医学进展, 2021, 42(3): 7-11.
|
|
Wang C J, Qu G G, Wu Y X, et al. Expression and activity identification of mono-specific anti-PCV 2 cap bivalent nanobody. Progress in Veterinary Medicine, 2021, 42(3): 7-11.
|
[18] |
张俊毅. 赭曲霉毒素A五价纳米抗体的表达及其免疫亲和柱的制备. 南昌: 南昌大学, 2018.
|
|
Zhang J Y. Expression of ochratoxin A pentavalent nanobody and preparation of immunoaffinity column. Nanchang: Nanchang University, 2018.
|
[19] |
Chatalic K L S, Veldhoven-Zweistra J, Bolkestein M, et al. A novel 111In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer. Journal of Nuclear Medicine, 2015, 56(7): 1094-1099.
doi: 10.2967/jnumed.115.156729
|
[20] |
Goldman E R, Broussard A, Anderson G P, et al. Bglbrick strategy for the construction of single domain antibody fusions. Heliyon, 2017, 3(12): e00474.
doi: 10.1016/j.heliyon.2017.e00474
|
[21] |
Sodee D B, Ellis R J, Samuels M A, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. The Prostate, 1998, 37(3): 140-148.
doi: 10.1002/(SICI)1097-0045(19981101)37:3<140::AID-PROS3>3.0.CO;2-Q
|
[22] |
Hennrich U, Eder M. [(68) Ga]Ga-PSMA-11: the first FDA-approved 68 Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel, Switzerland), 2021, 14(8): 713.
|
[23] |
Rosar F, Hau F, Bartholomä M, et al. Molecular imaging and biochemical response assessment after a single cycle of [(225) Ac]Ac-PSMA-617/[(177) Lu] Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu] Lu-PSMA-617 monotherapy. Theranostics, 2021, 11(9): 4050-4060.
doi: 10.7150/thno.56211
|
[24] |
Cimadamore A, Mazzucchelli R, Lopez-Beltran A, et al. Prostate cancer in 2021: novelties in prognostic and therapeutic biomarker evaluation. Cancers, 2021, 13(14): 3471.
doi: 10.3390/cancers13143471
|
[25] |
Miyahira A K, Soule H R. The 24th Annual Prostate Cancer Foundation scientific retreat report. The Prostate, 2018, 78(12): 867-878.
|
[26] |
Giraudet A L, Kryza D, Hofman M, et al. PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going? Therapeutic Advances in Medical Oncology, 2021, 13: 17588359211053898.
|
[27] |
穆博帅, 徐洋, 刘志博. 靶向PSMA放射性小分子药物研究进展. 同位素, 2021, 34(6): 565-580.
|
|
Mu B S, Xu Y, Liu Z B. Research progress of PSMA-targeted small molecule drugs. Journal of Isotopes, 2021, 34(6): 565-580.
|
[28] |
Hosseindokht M, Bakherad H, Zare H. Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancer. Cancer Cell International, 2021, 21(1): 580.
doi: 10.1186/s12935-021-02285-0
pmid: 34717636
|
[29] |
Tykvart J, Navrátil V, Sedlák F, et al. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). The Prostate, 2014, 74(16): 1674-1690.
doi: 10.1002/pros.22887
|
[30] |
Nováková Z, Foss C A, Copeland B T, et al. Novel monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) as research and theranostic tools. The Prostate, 2017, 77(7): 749-764.
doi: 10.1002/pros.23311
|
[31] |
Schülke N, Varlamova O A, Donovan G P, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(22): 12590-12595.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|